Mainz Biomed announced the commercial launch of ColoAlert in Poland, made possible through a strategic collaboration with test DNA Sp. z o. o. Sp. K. The partnership marks another significant step forward in providing new and innovative testing options to underserved populations in the battle against colorectal cancer, or CRC.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MYNZ:
- Mainz Biomed Announces Live Launch of ColoAlert® with testDNA Laboratory in Poland
- Mainz Biomed price target lowered to $7 from $10 at H.C. Wainwright
- Mainz Biomed Announces Financial Half Year Results 2023 and Provides Corporate Update
- Mainz Biomed launches ColoAlert with Marylebone Laboratory in the UK
- Mainz Biomed Announces Live Launch of ColoAlert® with Marylebone Laboratory in the United Kingdom